Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
Everolimus is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ BC) in combination with exemestane, after failure of treatment with letrozole or anastrozole.
...
Comprehensive Blood and Cancer Center Dept. of CBCC (2), Bakersfield, California, United States
New York Oncology Hematology NYOH Amsterdam, Albany, New York, United States
Texas Oncology Charles A. Sammons Cancer Ctr, Dallas, Texas, United States
Hotel Dieu de Paris, Paris, France
Massachusetts General Hospital, Boston, Massachusetts, United States
Beth Israel Deaconsess Medical Center, Boston, Massachusetts, United States
University of Texas Southwestern Medical Center SimmonsComprehensiveCancerCtr., Dallas, Texas, United States
Mercy Medical Center Medical Oncology & Hematology, Baltimore, Maryland, United States
Crescent City Research Consortium, LLC Dept of Hem&Onc Specialist - 2, Metairie, Louisiana, United States
Novartis Investigative Site, Southampton, United Kingdom
Retina-Vitreous Associates Medical Group, Beverley Hills, California, United States
Discover Vision Center, Independence, Missouri, United States
University of Minnesota Children's Hospital - Fairview, Minneapolis, Minnesota, United States
UT Southwestern Medical Center, Dallas, Texas, United States
Baylor College of Medicine, Houston, Texas, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Duke University Medical Center, Durham, North Carolina, United States
University of California, San Francisco, San Francisco, California, United States
University of California Davis Cancer Center, Sacramento, California, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.